4.4 Review

Gene and cell-mediated therapies for muscular dystrophy

Journal

MUSCLE & NERVE
Volume 47, Issue 5, Pages 649-663

Publisher

WILEY
DOI: 10.1002/mus.23738

Keywords

cell therapy; Duchenne muscular dystrophy; dystrophin; gene therapy; stem cells

Funding

  1. NIAMS NIH HHS [R37 AR040864] Funding Source: Medline
  2. NIA NIH HHS [R01 AG033610] Funding Source: Medline
  3. NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR040864] Funding Source: NIH RePORTER
  4. NATIONAL INSTITUTE ON AGING [R01AG033610] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Duchenne muscular dystrophy (DMD) is a devastating muscle disorder that affects 1 in 3,500 boys. Despite years of research and considerable progress in understanding the molecular mechanism of the disease and advancement of therapeutic approaches, there is no cure for DMD. The current treatment options are limited to physiotherapy and corticosteroids, and although they provide a substantial improvement in affected children, they only slow the course of the disorder. On a more optimistic note, more recent approaches either significantly alleviate or eliminate muscular dystrophy in murine and canine models of DMD and importantly, many of them are being tested in early phase human clinical trials. This review summarizes advancements that have been made in viral and nonviral gene therapy as well as stem cell therapy for DMD with a focus on the replacement and repair of the affected dystrophin gene. Muscle Nerve 47: 649663, 2013

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available